CD274 and non-small cell lung carcinoma: Regardless of PD-L1 expression and gene alterations in patients with metastatic NSCLC who did not receive chemotherapy, the PFS (8.3 months vs. 6.8 months) and OS (19.2 months vs. 14.7 months) of patients in the chemotherapy ± atezolizumab + bevacizumab group (ABCP group) were significantly longer than those of patients in the chemotherapy + bevacizumab group (BCP group) (57).